Norway's infliximab experience shows effect of deep price cuts on biosimilar success
This article was originally published in Scrip
What's the secret to biosimilar success? A two-thirds discount to the price of the reference drug. It's not as simple as that, of course, but recent experience with biosimilar infliximab in Norway suggests that in some cases there is a tipping point beyond which resistance to switching patients to a biosimilar may melt away under strong financial pressure.